Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion

Diabetologia

Volumn 43, Issue 7, 2000, Pages 852-858

  Fritsche, A ^b   Stefan, N ^b   Hardt, E ^b   Haring H ^b   Stumvoll, M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

Arginine; GLP 1; Insulin resistance; Type II diabetes

Indexed keywords

ARGININE; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0033912350     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051461     Document Type: Article

References (31)

1. DeFronzo RA (1988) The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 37: 667-687
2. Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13: 415-431
3. Yki-Järvinen H (1995) Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 38: 1378-1388
4. Köbberling J, Tillil H (1982) Empirical risk figures for first- degree relatives of non-insulin-dependent diabetics. In: Köbberling J, Tattersall R (eds) The genetics of diabetes mellitus. Academic Press, London pp 202-209
5. Heine RJ, Nijpels G, Mooy JM (1996) New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med 13: S12-S14
6. Lillioja S, Mott DM, Howard BV et al. (1988) Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318: 1217-1225
7. Eriksson J, Franssila-Kallunki A, Ekstand A et al. (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321: 337-343
8. Kolterman OG, Gray RS, Griffin J et al. (1981) Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest 68: 957-969
9. Pimenta W, Mitrakou A, Jensen T, Yki-Järvinen H, Daily G, Gerich J (1996) Insulin secretion and insulin sensitivity in people with impaired glucose tolerance. Diabet Med 13: S33-S36
10. Byrne M, Sturis J, Sobel RJ, Polonsky KS (1996) Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function. Am J Physiol 270: E572-E579
11. O'Rahilly SP, Rudenski A, Burnett MA et al. (1986) Beta-cell dysfunction rather than insulin insensitivity is the primary defect in familial type 2 diabetes. Lancet ii: 360-364
12. Ahren B, Larsson H, Holst JJ (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137: 127-131
13. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
14. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W (1998) Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21: 1925-1931
15. Schmidt HH, Warner TD, Ishii K, Sheng H, Murad F (1992) Insulin secretion from pancreatic B cells caused by L-arginine- derived nitrogen oxides. Science 255: 721-723
16. Larsson H, Berglund G, Ahren B (1995) Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 80: 1778-1782
17. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74: 1318-1328
18. World Health Organization Expert Committee Second report on diabetes mellitus (1980) Technical report series No 646, WHO, Geneva
19. Pimenta W, Korytkowski M, Mitrakou A et al. (1995) Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 273: 1855-1861
20. Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661
21. Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377
22. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J (1980) Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51: 520-528
23. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in Type II (non-insulin-dependent) diabetes. Diabetologia 29: 46-52
24. Karlsson S, Fridolf T, Ahren B (1994) Islet mechanism of CCK-8 and GLP-1 (7-36) amide. In: Flatt P, Lenzen S (eds) Frontiers of insulin secretion and pancreatic b-cell research. Smith-Gordon Nishimura, Singapore pp 337-351
25. Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF (1999) cAMP-dependent mobilization of intracellular Ca2 + stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2 + signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1- (7-37). J Biol Chem 274: 14147-14156
26. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P (1998) Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47: 57-65
27. Drucker DJ (1998) Glucagon-like peptides. Diabetes 47: 159-169
28. Spinas GA, Laffranchi R, Francoys I, David I, Richter C, Reinecke M (1998) The early phase of glucose-stimulated insulin secretion requires nitric oxide. Diabetologia 41: 292-299
29. Blachier F, Mourtada A, Sener A, Malaisse WJ (1989) Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. Endocrinology 124: 134-141
30. Ganda OP, Srikanta S, Brink SJ et al. (1984) Differential sensitivity to beta-cell secretagogues in "early" type I diabetes mellitus. Diabetes 33: 516-521
31. Rachman J, Barrow BA, Levy JC, Turner RC (1997) Nearnormalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211